Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer
March 9th 2025, 12:43pm
PER® Miami Breast Cancer Conference
Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
March 8th 2025, 7:13pm
PER® Miami Breast Cancer Conference
Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.
Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions
March 8th 2025, 5:35pm
PER® Miami Breast Cancer Conference
Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.
Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer
March 8th 2025, 5:20pm
PER® Miami Breast Cancer Conference
Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.
Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups
March 8th 2025, 4:18pm
PER® Miami Breast Cancer Conference
Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.
Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer
March 8th 2025, 3:55pm
PER® Miami Breast Cancer Conference
Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.
Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
March 8th 2025, 3:49pm
PER® Miami Breast Cancer Conference
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
March 8th 2025, 1:19pm
PER® Miami Breast Cancer Conference
Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.
Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas
March 8th 2025, 11:00am
PER® Miami Breast Cancer Conference
Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.
HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options
March 7th 2025, 9:54pm
PER® Miami Breast Cancer Conference
Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.
PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer
March 7th 2025, 9:32pm
PER® Miami Breast Cancer Conference
PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.
Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC
March 7th 2025, 9:21pm
PER® Miami Breast Cancer Conference
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.
Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer
March 7th 2025, 9:10pm
PER® Miami Breast Cancer Conference
PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer
March 7th 2025, 8:40pm
PER® Miami Breast Cancer Conference
Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.
Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer
March 7th 2025, 8:29pm
PER® Miami Breast Cancer Conference
Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.
Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer
March 7th 2025, 7:37pm
PER® Miami Breast Cancer Conference
Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.
Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population
March 7th 2025, 7:05pm
PER® Miami Breast Cancer Conference
Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.
Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2-Negative Metastatic Breast Cancer
March 7th 2025, 6:24pm
PER® Miami Breast Cancer Conference
The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.
Ribociclib Efficacy Is Maintained With Dose Reductions in HR+/HER2-Negative Early Breast Cancer
March 7th 2025, 6:01pm
PER® Miami Breast Cancer Conference
A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.
Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC
March 7th 2025, 2:00pm
PER® Miami Breast Cancer Conference
Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.